A 72-year-old woman who received a denosumab (Prolia) injection a few days ago is scheduled for dental work in two weeks; should she proceed with the dental procedure now or postpone it?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 8, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Proceed with Dental Work as Planned

She can safely proceed with the dental work in two weeks. Since the Prolia injection was given only a couple of days ago, and the dental procedure is scheduled for approximately two weeks post-injection, this timing is actually favorable and does not require postponement.

Reasoning Based on Guidelines

The 2019 Endocrine Society guidelines address osteonecrosis of the jaw (ONJ) risk with denosumab (Prolia) and provide clear direction 1. The key considerations are:

ONJ Risk in Osteoporosis Patients

  • The absolute risk of ONJ in osteoporosis patients on denosumab is extremely low, estimated at 1 in 10,000 to 1 in 100,000 (0.001% to 0.01%) 1
  • This risk is substantially lower than the oncologic dose used in cancer patients
  • Tooth extraction in patients exposed to antiresorptive therapy carries approximately a 0.5% risk of developing ONJ 1

Timing Considerations

The American Dental Association does not recommend stopping denosumab for dental procedures 1. However, the guidelines note that if invasive dental procedures are planned, initiation of potent antiresorptive therapy could be deferred until the area healed 1. Since she has already received the injection, this is not applicable.

The ASCO/MASCC guidelines recommend that if dentoalveolar surgery is necessary, therapy should be deferred until complete healing occurs 2. However, this applies to initiating therapy, not to procedures occurring shortly after an injection has already been given.

Critical Distinction: Osteoporosis vs. Oncologic Dosing

Research evidence shows the risk profile differs dramatically:

  • Osteoporosis dosing (60 mg every 6 months): 2.3% ONJ risk with extractions 3
  • Oncologic dosing (120 mg monthly): Much higher risk, up to 28.7% 4

Your patient is on the osteoporosis regimen, placing her in the lower-risk category.

Practical Management Recommendations

Before the Dental Procedure:

  • Ensure good oral hygiene leading up to the appointment 1, 2
  • Verify adequate calcium and vitamin D supplementation 5
  • Consider prophylactic antibacterial mouth rinse 1

During and After the Procedure:

  • If extractions are performed, request primary wound closure using proper surgical technique 6
  • The dentist should smooth bone edges and achieve tension-free closure 6
  • Schedule systematic follow-up every 6-8 weeks until complete mucosal healing 2

Important Caveats:

Do not delay or skip the next scheduled Prolia injection (due in approximately 6 months). Unlike bisphosphonates, denosumab does not accumulate in bone and stopping it causes rapid bone loss and increased vertebral fracture risk 1. The rebound effect can result in BMD decreases of 6.6% in the lumbar spine and 5.3% in the total hip within 12 months of discontinuation 1.

What to Avoid

  • Do not request a "drug holiday" - this concept applies to bisphosphonates after >4 years of therapy, not to denosumab 1
  • Do not postpone necessary dental work - delaying treatment of infected or problematic teeth actually increases ONJ risk 4
  • Do not plan elective dental implants during active denosumab therapy 2

The timing of her injection (a few days ago) with dental work in two weeks presents no contraindication. The procedure should proceed as scheduled with appropriate preventive measures and follow-up care.

References

Research

What is the Risk of Developing Osteonecrosis Following Dental Extractions for Patients on Denosumab for Osteoporosis?

Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2023

Research

Denosumab-related osteonecrosis of the jaw after tooth extraction and the effects of a short drug holiday in cancer patients: a multicenter retrospective study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2021

Guideline

prostate cancer, version 3.2026, nccn clinical practice guidelines in oncology.

Journal of the National Comprehensive Cancer Network : JNCCN, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.